LAG-3 Combination Therapy for Stronger Anti-Tumor Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for LAG-3 positive tumors are inadequate in effectively inhibiting tumor growth and inducing anti-tumor activity.
Innovation Solution
Administering a combination of a LAG-3 antagonist, a PD-1 pathway inhibitor, and one or more chemotherapeutic agents to patients with LAG-3 positive tumors to enhance immune response and inhibit tumor growth.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a LAG-3 antagonist is administered alone, then immune activation is enhanced, but anti-tumor activity is insufficient
Solution Approach 1:
The patent combines a LAG-3 antagonist with a PD-1 pathway inhibitor and chemotherapeutic agents into a multi-component therapy regimen. This merging of different therapeutic mechanisms synergistically enhances both immune activation and anti-tumor activity, resolving the contradiction where single-agent LAG-3 inhibition provides immune activation but insufficient anti-tumor effect.
Solution Approach 2:
The therapy functions as a composite treatment system integrating multiple agents with different modes of action: LAG-3 antagonist for immune activation, PD-1 pathway inhibitor for immune checkpoint blockade, and chemotherapeutic agents for direct tumor cell killing. This composite approach achieves superior anti-tumor activity compared to any single component.
2Productivity
If a PD-1 pathway inhibitor is administered alone, then immune resistance is overcome, but treatment efficacy is limited
Solution Approach 1:
The combination therapy merges PD-1 pathway inhibition with LAG-3 antagonism and chemotherapeutic agents. This synergistic combination overcomes immune resistance more effectively than PD-1 inhibition alone while improving overall treatment efficacy through multiple concurrent mechanisms of action.
Solution Approach 2:
The therapy segments the immune response modulation into multiple components: LAG-3 blockade for T cell activation, PD-1 inhibition for checkpoint removal, and chemotherapy for tumor cell destruction. This segmentation allows each component to address specific aspects of tumor immunity, collectively enhancing treatment efficacy.
3Productivity
If chemotherapeutic agents are used alone, then tumor growth is inhibited, but immune activation is insufficient
Solution Approach 1:
The patent merges chemotherapeutic agents with immunotherapy components (LAG-3 antagonist and PD-1 pathway inhibitor). This combination maintains tumor growth inhibition through chemotherapy while simultaneously activating the immune system through immunotherapy, resolving the contradiction where chemotherapy alone provides tumor killing but insufficient immune activation.
4Reliability
If combination therapy is administered, then treatment outcomes are improved, but treatment complexity increases
Solution Approach 1:
While combining multiple agents does increase treatment complexity, the patent manages this through a structured regimen where the LAG-3 antagonist, PD-1 pathway inhibitor, and chemotherapeutic agents are administered in a coordinated manner. The combination achieves superior treatment outcomes by targeting multiple pathways simultaneously, with the complexity managed through established protocols and monitoring frameworks.
Data Source
AI summary
The invention provides a method of treating a tumor in a human gastric cancer or gastroesophageal junction cancer patient.